Back to search
FDAFDA · Food and drugs·Recall number D-068-2013

Arranon (nelarabine) Injection 5mg/mL, 50mL Vials, Rx only, For I.V. Infusion only, GlaxoSmith Kline, Research Triangle Park, NC 27709. Made in England, NDC 0007-4401-06

Published December 5, 2012 · Recall initiated: October 8, 2012

Summary

FDA records drug Class II recall D-068-2013, published December 5, 2012 and initiated October 8, 2012. Recalling firm: GlaxoSmithKline, LLC.; Status: Terminated; Reported quantity: 1,319 vials; Lot: Lot # C536707 Exp 02/14, C538830 Exp.02/14, C533169 Exp. 02/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Impurities/Degradation Products: Potential for drug related impurities to exceed the specification limits.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
GlaxoSmithKline, LLC.
Distributor
Nationwide
Lot
Lot # C536707 Exp 02/14, C538830 Exp.02/14, C533169 Exp. 02/14
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Arranon (nelarabine) Injection 5mg/mL, 50mL Vials, Rx only, For I.V. Infusion only, GlaxoSmith Kline, Research Triangle Park, NC 27709. Made in England, NDC 0007-4401-06 recalled?

Yes. FDA published recall D-068-2013 on December 5, 2012. Reported hazard: Impurities/Degradation Products: Potential for drug related impurities to exceed the specification limits.

What should I do if I have this product?

Voluntary: Firm initiated · Letter